Update shared on05 Sep 2025
Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks.
Analyst Commentary
- Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.
- Favorable impact from foreign exchange movements and recent M&A activity contributing to growth outlook.
- Increased speculation around a potential buyout has driven added investor interest in the shares.
- Fiscal 2025 estimates considered reasonable, with Street forecasts now better aligned to actual demand trends and tariff risks.
- Shares remain undervalued relative to historical norms and peers, presenting an attractive entry point according to bullish analysts.
What's in the News
- Completed repurchase of 7,996,191 shares (3.5% of outstanding) for $562.74 million under its buyback program.
- Raised full-year 2025 earnings guidance: revenue now expected to be $4,081–$4,091 million and GAAP EPS $2.56–$2.59.
- Provided Q4 2025 guidance: revenue expected at $1,030–$1,040 million and GAAP EPS $0.90–$0.93.
- Dropped from the Russell 1000 Dynamic Index.
Valuation Changes
Summary of Valuation Changes for Hologic
- The Consensus Analyst Price Target remained effectively unchanged, at $73.87.
- The Discount Rate for Hologic remained effectively unchanged, moving only marginally from 7.84% to 7.83%.
- The Future P/E for Hologic remained effectively unchanged, moving only marginally from 19.51x to 19.50x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.